1256353-15-7

Upstream product

• 7418-65-7 4-aminonicotinic acid 
• 77287-34-4 formamide 
• 52834-08-9 4-amino-5-bromonicotinic acid 

Downstream Products

• 1269421-62-6 8-bromo-N,N-bis(4-methoxybenzyl)pyrido[4,3-d]pyrimidin-4-amine 
• 1269421-63-7 methyl 4-(bis(4-methoxybenzyl)amino)pyrido[4,3-d]pyrimidine-8-carboxylate 
• 1269421-60-4 4-(bis(4-methoxybenzyl)amino)pyrido[4,3-d]pyrimidine-8-carboxylic acid 
• 1269421-69-3 4-(bis(4-methoxybenzyl)amino)-N-(2,6-difluoro-3-(propylsulfonamido)phenyl)pyrido[4,3-d]pyrimidine-8-carboxamide 
• 1269420-22-5 4-amino-pyrido[4,3-d]pyrimidine-8-carboxylic acid [2,6-difluoro-3-(propane-1-sulfonylamino)-phenyl]-amide 

Relevant academic research and scientific papers

PYRIMIDO-DIAZEPINONE COMPOUND

Provided are a compound represented by general formula (I), or the pharmaceutically acceptable salt thereof, (wherein Ra represents a hydrogen atom or the like, R1 and R2 may be the same or different, and each represents a hydrogen atom, optionally substituted lower alkyl or cycloalkyl, or R1 and R2 are combined together with the adjacent nitrogen atom thereto to form nitrogen-containing heterocyclic group, and Z represents a bicyclic heterocyclic group in which optionally substituted two six-membered rings are fused to each other, or the like) and the like.

RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF

Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.